Kalaris Therapeutics Inc (KLRS) NASDAQ
8.67
-0.5(-5.45%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.67
-0.5(-5.45%)
Currency In USD
| Previous Close | 9.17 |
| Open | 9.07 |
| Day High | 9.07 |
| Day Low | 8.55 |
| 52-Week High | 12.9 |
| 52-Week Low | 2.14 |
| Volume | 32,227 |
| Average Volume | 92,921 |
| Market Cap | 162.15M |
| PE | -0.23 |
| EPS | -38.05 |
| Moving Average 50 Days | 9.41 |
| Moving Average 200 Days | 5.74 |
| Change | -0.5 |
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
GlobeNewswire Inc.
Jan 28, 2026 9:05 PM GMT
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
GlobeNewswire Inc.
Dec 17, 2025 10:59 PM GMT
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal disea
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
GlobeNewswire Inc.
Dec 17, 2025 9:01 PM GMT
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower